Special Reports
Refine Search
Biotechnology
Total investment in biopharma M&A in the first quarter of 2023 was over four times the equivalent value for first quarter 2022, including the first megadeal since December 2020 with Pfizer paying $43 billion to acquire Seagen. 3 May 2023
Pharmaceutical
Jürgen Polifka, Director of Global Market Access at Advanz Pharma, provides a Special Report on the company's approach to securing rapid access for essential medicines. 17 December 2021
Pharmaceutical
A Special Report on the top five trends redefining the way healthcare stakeholders look at long-term healthcare access sustainability in the region from Roshel Jayasundera, director, Global Consulting, Axios International. 28 April 2021
Pharmaceutical
Reducing patient healthcare costs is imperative, write Matthew Majewski and Andrew Parece, vice presidents of Charles River Associates, in a Special Report. 21 October 2020
Biosimilars
A Special Report from Tokyo-based Patrick Branch from LEK Consulting on the macro trends pointing towards rapid growth in Japan’s biosimilars market. 17 June 2020
Biotechnology
In a Special Report, Patrick Laroche, Janssen EMEA Haematology Therapy Area Lead, looks at how haematology is leading the way in oncology innovation, how CAR-T has the potential to revolutionise treatment for multiple myeloma, and the challenges that lie ahead in this field. 28 January 2020
Pharmaceutical
For our latest Special Report, Adriaan Fruijtier from CATS Consultants, gives an account of major talking points at one of the year’s major events in the calendar of the Regulatory Affairs Professionals Society (RAPS), which took place in Brussels earlier in the summer. 22 July 2019
Pharmaceutical
Joseph Saba, chief executive of Axios International, a healthcare organization specialized in access in developing countries, writes an exclusive Special Report for The Pharma Letter. 9 January 2019
Pharmaceutical
In a special report piece, Ed Corbett, principal at specialist pharmaceutical strategy consultants, Novasecta, considers an issue of paramount importance to the future of the industry. 3 October 2018
Pharmaceutical
In our latest Special Report, Ali Hansford, head of social policy at the Association of the British Pharmaceutical Industry (ABPI), discusses the UK government's plans to invest £20 million ($27 million) more into the research, diagnosis and development of brain tumor treatments. She reflects on the work of pharma globally in this field. 18 May 2018
Biosimilars
Our latest Special Report is a review of key factors impeding progress of US biosimilar adoption written by Helen Ji, an associate at Schiff Hardin LLP, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines. 4 April 2018
Pharmaceutical
The final Special Report of 2017 comes from Scott Pescatore, the Europe region general manager for rare diseases at Novartis Oncology, and is an overview of how progress has been made, and how more can be achieved, in the orphan medicines space. 19 December 2017
Pharmaceutical
Science writer David Levine provides the latest quarterly Special Report piece, looking at the drug prices in one therapy area that are getting on people's nerves so much that they might prompt drastic action from the White House to bring down the cost of medicines across the board. 29 September 2017
Biosimilars
In a quarterly Special Report piece, Andrew Williams, patent law expert, partner at Chicago-based IP law firm McDonnell Boehnen Hulbert & Berghoff and chair of its Patent Trial and Appeal Board (PTAB) Trials Practice Group, writes about a crucial case affecting the marketing of biosimilars in the USA. 25 July 2017
Pharmaceutical
Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD), has been generating grave concern throughout the medical community, writes Thomas Liquard, chief executive of Australian biopharma Immuron, in his overview of the race to market effective treatments for this condition which is our first quarterly Special Report of 2017. 30 March 2017
Pharmaceutical
Our quarterly Special Report from experts at QuintilesIMS provides scientific and practical insights on Post Authorization Safety Studies based on the first three years since implementation of the new European Union legislation, offering forecasts for likely advances in 2017. 29 December 2016
Biosimilars
In our quarterly special report, Dr Michelle Maxwell examines the fast-moving world of biosimilars and explores the opportunities opening up for biosimilar developers as patent exclusivity expires on numerous biologic medicines over the next ten years. 8 September 2016
Pharmaceutical
In our quarterly special report Dr Michelle Maxwell takes an in-depth look at the history of personalized medicines and their future potential. 9 June 2016
Biotechnology
In our quarterly special report, Michelle Maxwell takes an in-depth look at immunotherapies, which are among the most promising treatments in current pharmaceutical development. 7 March 2016
Biotechnology
Total investment in biopharma M&A in the first quarter of 2023 was over four times the equivalent value for first quarter 2022, including the first megadeal since December 2020 with Pfizer paying $43 billion to acquire Seagen. 3 May 2023
Pharmaceutical
Jürgen Polifka, Director of Global Market Access at Advanz Pharma, provides a Special Report on the company's approach to securing rapid access for essential medicines. 17 December 2021
Pharmaceutical
A Special Report on the top five trends redefining the way healthcare stakeholders look at long-term healthcare access sustainability in the region from Roshel Jayasundera, director, Global Consulting, Axios International. 28 April 2021
Pharmaceutical
Reducing patient healthcare costs is imperative, write Matthew Majewski and Andrew Parece, vice presidents of Charles River Associates, in a Special Report. 21 October 2020
Biosimilars
A Special Report from Tokyo-based Patrick Branch from LEK Consulting on the macro trends pointing towards rapid growth in Japan’s biosimilars market. 17 June 2020
Biotechnology
In a Special Report, Patrick Laroche, Janssen EMEA Haematology Therapy Area Lead, looks at how haematology is leading the way in oncology innovation, how CAR-T has the potential to revolutionise treatment for multiple myeloma, and the challenges that lie ahead in this field. 28 January 2020
Pharmaceutical
For our latest Special Report, Adriaan Fruijtier from CATS Consultants, gives an account of major talking points at one of the year’s major events in the calendar of the Regulatory Affairs Professionals Society (RAPS), which took place in Brussels earlier in the summer. 22 July 2019
Pharmaceutical
Joseph Saba, chief executive of Axios International, a healthcare organization specialized in access in developing countries, writes an exclusive Special Report for The Pharma Letter. 9 January 2019
Pharmaceutical
In a special report piece, Ed Corbett, principal at specialist pharmaceutical strategy consultants, Novasecta, considers an issue of paramount importance to the future of the industry. 3 October 2018
Pharmaceutical
In our latest Special Report, Ali Hansford, head of social policy at the Association of the British Pharmaceutical Industry (ABPI), discusses the UK government's plans to invest £20 million ($27 million) more into the research, diagnosis and development of brain tumor treatments. She reflects on the work of pharma globally in this field. 18 May 2018
Biosimilars
Our latest Special Report is a review of key factors impeding progress of US biosimilar adoption written by Helen Ji, an associate at Schiff Hardin LLP, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines. 4 April 2018
Pharmaceutical
The final Special Report of 2017 comes from Scott Pescatore, the Europe region general manager for rare diseases at Novartis Oncology, and is an overview of how progress has been made, and how more can be achieved, in the orphan medicines space. 19 December 2017
Pharmaceutical
Science writer David Levine provides the latest quarterly Special Report piece, looking at the drug prices in one therapy area that are getting on people's nerves so much that they might prompt drastic action from the White House to bring down the cost of medicines across the board. 29 September 2017
Biosimilars
In a quarterly Special Report piece, Andrew Williams, patent law expert, partner at Chicago-based IP law firm McDonnell Boehnen Hulbert & Berghoff and chair of its Patent Trial and Appeal Board (PTAB) Trials Practice Group, writes about a crucial case affecting the marketing of biosimilars in the USA. 25 July 2017
Pharmaceutical
Non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD), has been generating grave concern throughout the medical community, writes Thomas Liquard, chief executive of Australian biopharma Immuron, in his overview of the race to market effective treatments for this condition which is our first quarterly Special Report of 2017. 30 March 2017
Pharmaceutical
Our quarterly Special Report from experts at QuintilesIMS provides scientific and practical insights on Post Authorization Safety Studies based on the first three years since implementation of the new European Union legislation, offering forecasts for likely advances in 2017. 29 December 2016
Biosimilars
In our quarterly special report, Dr Michelle Maxwell examines the fast-moving world of biosimilars and explores the opportunities opening up for biosimilar developers as patent exclusivity expires on numerous biologic medicines over the next ten years. 8 September 2016
Pharmaceutical
In our quarterly special report Dr Michelle Maxwell takes an in-depth look at the history of personalized medicines and their future potential. 9 June 2016
Biotechnology
In our quarterly special report, Michelle Maxwell takes an in-depth look at immunotherapies, which are among the most promising treatments in current pharmaceutical development. 7 March 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze